AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders.
abreva® (docosanol 10% cream)
AVP-923 for PBA MIF Inhibitor AVP-923 for Diabetic Peripheral Neuropathic Pain
AVP-923 for Pseudobulbar Affect (PBA)
Canaccord 2010 Growth Conference WebcastDate: Aug 10, 2010Begins: 5:00 p.m. ET
Fiscal 2010 Third Quarter Conference CallDate: Aug 05, 2010Begins: 11:00 a.m. ET
Wedbush 2010 Life Sciences Conference WebcastDate: Aug 03, 2010Begins: 3:35 p.m. ET
Aug 05, 2010AVANIR Pharmaceuticals Announces Fiscal 2010 Third Quarter Financial Results
Aug 03, 2010AVANIR to Present at the Canaccord Genuity Growth Conference
Jul 29, 2010AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
abreva® (docosanol 10% cream)
